Clinical Research Directory

Browse clinical research sites, groups, and studies.

1 clinical study listed.

Healthy volunteers

Filters:

PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer

Tundra lists 1 PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer clinical trial. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07111832

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

This study is to evaluate the progression-free survival (PFS) of SHR-A1811 combined with SHR-1316 in the first-line treatment of PD-L1-positive locally recurrent unresectable or metastatic triple-negative breast cancer with Toripalimab combined with Nab-paclitaxel, as assessed by blinded independent central review (BICR).

Gender: FEMALE

Ages: 18 Years - 75 Years

Updated: 2025-12-18

2 states

PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer